×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CANF – can-fite biopharma ltd sponsored adr (israel) (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CANF
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/31
09:56 am
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
12/30
07:12 am
canf
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson [Yahoo! Finance]
Low
Report
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson [Yahoo! Finance]
12/30
07:00 am
canf
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Low
Report
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
12/13
02:06 am
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
12/5
11:05 pm
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
High
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
12/5
08:01 am
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
12/4
07:15 am
canf
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite's Namodenoson Drug [Yahoo! Finance]
High
Report
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite's Namodenoson Drug [Yahoo! Finance]
12/4
07:00 am
canf
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
High
Report
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/30
07:01 am
canf
Form 6-K Can-Fite BioPharma Ltd. For: Dec 30
Medium
Report
Form 6-K Can-Fite BioPharma Ltd. For: Dec 30
12/4
07:05 am
canf
Form 6-K Can-Fite BioPharma Ltd. For: Dec 04
High
Report
Form 6-K Can-Fite BioPharma Ltd. For: Dec 04
11/14
04:49 pm
canf
Form SC 13G/A Can-Fite BioPharma Ltd. Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G/A Can-Fite BioPharma Ltd. Filed by: ARMISTICE CAPITAL, LLC
11/12
09:23 am
canf
Form 6-K Can-Fite BioPharma Ltd. For: Nov 11
Low
Report
Form 6-K Can-Fite BioPharma Ltd. For: Nov 11
11/4
07:10 am
canf
Form 6-K Can-Fite BioPharma Ltd. For: Nov 04
Medium
Report
Form 6-K Can-Fite BioPharma Ltd. For: Nov 04
10/18
09:24 am
canf
Form 6-K Can-Fite BioPharma Ltd. For: Oct 18
Low
Report
Form 6-K Can-Fite BioPharma Ltd. For: Oct 18
10/9
07:03 am
canf
Form 6-K Can-Fite BioPharma Ltd. For: Oct 09
Medium
Report
Form 6-K Can-Fite BioPharma Ltd. For: Oct 09
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/29
Visiongain Report Claims There is Huge Potential Within the $39bn Dermatological Drugs Market
43.6%
12/26 Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing 30.5%
3/5 Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus 24.5%
9/10 Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays 23.2%
4/13 Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately 22.5%
4/2 Form 6-K/A Can-Fite BioPharma Ltd. For: Apr 02 17.2%
3/11 Form 6-K Can-Fite BioPharma Ltd. For: Mar 11 16.0%
1/3 New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss 12.8%
5/30 Form SC 13D Can-Fite BioPharma Ltd. Filed by: Capital Point Ltd. 9.4%
2/12 Form 6-K Can-Fite BioPharma Ltd. For: Feb 12 8.9%
12/26 Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing 30.5%
3/5 Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus 24.5%
9/10 Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays 23.2%
4/13 Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately 22.5%
4/2 Form 6-K/A Can-Fite BioPharma Ltd. For: Apr 02 17.2%
3/11 Form 6-K Can-Fite BioPharma Ltd. For: Mar 11 16.0%
1/3 New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss 12.8%
5/30 Form SC 13D Can-Fite BioPharma Ltd. Filed by: Capital Point Ltd. 9.4%
2/12 Form 6-K Can-Fite BioPharma Ltd. For: Feb 12 8.9%
TOP News Decliners
5/20
Can-Fite BioPharma Announces $6 Million Registered Direct Offering
-53.0%
10/17 Form 6-K Can-Fite BioPharma Ltd. For: Oct 17 -48.6%
2/10 Can-Fite BioPharma Announces Pricing of $5 Million Public Offering -43.4%
1/9 Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million -19.7%
3/13 Form 6-K Can-Fite BioPharma Ltd. For: Mar 13 -19.4%
10/31 Can-Fite up 36% premarket on advancement of Namodenoson [Seeking Alpha] -19.3%
8/1 Form 6-K Can-Fite BioPharma Ltd. For: Aug 01 -19.2%
4/7 Form 6-K Can-Fite BioPharma Ltd. For: Apr 07 -18.8%
2/27 Form 6-K Can-Fite BioPharma Ltd. For: Feb 27 -16.8%
3/23 Form 6-K Can-Fite BioPharma Ltd. For: Mar 23 -15.3%
10/17 Form 6-K Can-Fite BioPharma Ltd. For: Oct 17 -48.6%
2/10 Can-Fite BioPharma Announces Pricing of $5 Million Public Offering -43.4%
1/9 Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million -19.7%
3/13 Form 6-K Can-Fite BioPharma Ltd. For: Mar 13 -19.4%
10/31 Can-Fite up 36% premarket on advancement of Namodenoson [Seeking Alpha] -19.3%
8/1 Form 6-K Can-Fite BioPharma Ltd. For: Aug 01 -19.2%
4/7 Form 6-K Can-Fite BioPharma Ltd. For: Apr 07 -18.8%
2/27 Form 6-K Can-Fite BioPharma Ltd. For: Feb 27 -16.8%
3/23 Form 6-K Can-Fite BioPharma Ltd. For: Mar 23 -15.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: